ANDREW BRAGAGNINI: Open Payments
NPI 1629672308 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,234 in 116 payments from 24 companies in 2025. Trend: 2023 $1,933 · 2024 $2,441 · 2025 $2,234
Food & beverage: $2,234
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 14 | $311 |
| Amgen Inc. | 17 | $232 |
| Otsuka America Pharmaceutical, Inc. | 9 | $184 |
| Fresenius USA Marketing, Inc. | 9 | $150 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $140 |
| GlaxoSmithKline, LLC. | 8 | $127 |
| Vifor Pharma, Inc. | 6 | $126 |
| SHIELD THERAPEUTICS INC | 7 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $118 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $115 |
Products named: TARPEYO, KRYSTEXXA, JYNARQUE, JARDIANCE, VELPHORO, BENLYSTA, Veltassa, ACCRUFER.
Industry payments across LA — which companies pay providers there.
